title: Austrian clinical practice with anidulafungin in 2008: a multicenter survey.
abstract: Anidulafungin had demonstrated favorable efficacy versus fluconazole in a randomized trial on invasive Candida infections. Since patient characteristics in the post-approval use of antifungals likely deviate from clinical trials, we surveyed the use of anidulafungin in clinical routine. We performed a retrospective survey of the post-approval use of anidulafungin in 9 Austrian clinical centers. Anidulafungin was used in 129 critically ill patients with severe comorbidities and multiple risk factors. Indications were suspected invasive fungal infections (IFI) (61%), proven candidemia (19%), and at risk for IFI (prophylaxis, 20%). Candida colonization in conjunction with other risk factors prompted treatment in many patients. predominant pathogens were C. albicans, C. glabrata and C. krusei. Anidulafungin was mostly used for pre-emptive (69%) and first-line treatment (17%) of invasive candidiasis. Treatment response, i.e. complete response/stabilization as determined by investigators (89% in the overall population; 87% for documented candidemia) and survival rates (81% and 75%, respectively) were similar to previous trial data. No breakthrough IFI and few adverse events were reported. Overall, favorable clinical experiences were documented with anidulafungin in the clinical routine setting.
authors: Division of Hygiene and Medical Microbiology, Innsbruck Medical University, Innsbruck, Austria.
authors: S
authors: S
authors: Perkhofer
authors: M
authors: M
authors: Hell
authors: B
authors: B
authors: Gustorff
authors: A
authors: A
authors: Von Goedecke
authors: U
authors: U
authors: Illievich
authors: C
authors: C
authors: Kratzer
authors: W
authors: W
authors: Moosbauer
authors: P
authors: P
authors: Wimmer
authors: U
authors: U
authors: Zerlauth
authors: K
authors: K
authors: Nachbaur
authors: W
authors: W
authors: Vogel
authors: R
authors: R
authors: Bellmann
authors: F
authors: F
authors: Schwameis
authors: C
authors: C
authors: Lass-Flörl
mesh_terms: D000077612:Anidulafungin; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001317:Austria / Q000453:epidemiology; D002175:Candida / Q000145:classification / Q000302:isolation & purification; D058387:Candidemia / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology / Q000517:prevention & control; D002177:Candidiasis / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology / Q000517:prevention & control*; D058365:Candidiasis, Invasive / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology / Q000517:prevention & control; D015897:Comorbidity; D054714:Echinocandins / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008499:Medical Records; D010818:Practice Patterns, Physicians'; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D013997:Time Factors
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D000077612:Anidulafungin